Mersana enters $20mm loan facility with SVB; gets $5mm up front

15:40 EDT 14 May 2019 | Elsevier Business Intelligence

Mersana Therapeutics Inc. (antibody-drug conjugates for cancer) entered a $20mm non-dilutive term loan agreement with Silicon...

Original Article: Mersana enters $20mm loan facility with SVB; gets $5mm up front


More From BioPortfolio on "Mersana enters $20mm loan facility with SVB; gets $5mm up front"

Quick Search

Relevant Topics

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...